Login / Signup

Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.

Michael T SchweizerRoman GulatiTodd YezefskiHeather H ChengElahe MostaghelMichael C HaffnerRadhika A PatelNavonil De SarkarGavin HaRuth DumpitBrianna WooAaron LinPatrick PanlasiguiNerina McDonaldMichael LaiKatie NegaJeannette HammondPetros GrivasAndrew C HsiehBruce MontgomeryPeter S NelsonEvan Y Yu
Published in: Prostate cancer and prostatic diseases (2022)
BAT plus olaparib is associated with high response rates and long PFS. Clinical benefit was observed regardless of HRR gene mutational status.
Keyphrases
  • squamous cell carcinoma
  • small cell lung cancer
  • genome wide
  • copy number
  • middle aged
  • stem cells
  • gene expression
  • cell therapy
  • transcription factor
  • replacement therapy
  • genome wide analysis